chen, chenyan – page 12 – eisai china lnc.-爱游戏app官网入口

on august 22, the “2018 great suzhou best employer award ceremony” was held at suzhou jinji lake international convention center. eisai china inc. (eci) has been accredited great suzhou best employer for second consecutive years. the “best employer” selection project has been organized for 5 years since 2013. it is now the most influential and appealing event in suzhou for employer brand selection. this project has successfully attracted the participation of over one thousand enterprises and the attention of millions of employees and has become an annual ceremony for the display of employer brands in suzhou. 

aug. 4, 2018, china top 100 pharmaceutical enterprises list was released in the 35thchina pharmaceutical industry information annual conference 2018. following the 97th place in 2015, and the 92nd place in 2016, eisai (china) ranked 84th in the top 100 list 2017.

tokyo & kenilworth, n.j., july 31, 2018 – eisai co., ltd. and merck & co., inc. kenilworth, n.j., u.s.a. (nyse:mrk), known as msd outside the united states and canada, announced today that the u.s. food and drug administration (fda) granted breakthrough therapy designation for lenvima® (generic name: lenvatinib mesylate), the orally available kinase inhibitor discovered by eisai, in combination with merck & co., inc., kenilworth, n.j., u.s.a.’s anti-pd-1 therapy keytruda® (generic name: pembrolizumab) for the potential treatment of patients with advanced and/or metastatic non-microsatellite instability high (msi-h)/proficient mismatch repair (pmmr) endometrial carcinoma (ec) who have progressed following at least one prior systemic therapy.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announces today that a total of 13 presentations highlighting results from a phase ii clinical study (study 201) of the anti-amyloid beta (aβ) protofibril antibody ban2401 and a phase ii clinical study (study 202) of the oral bace (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: e2609) in addition to the latest data on its alzheimer‘s disease / dementia pipeline including anti-aβ antibody aducanumab, will be given at the alzheimer’s association international conference (aaic) 2018, in chicago from july 22 to 26, 2018. ban2401, elenbecestat and aducanumab are being jointly developed by eisai and biogen inc. (headquarters: cambridge, massachusetts, united states, “biogen”).

june 20, 2018, eisai china region held a grand launching campaign for its rk-1000 model a, a new generation of icg clearance meter, in jw marriott hotel shanghai. the staff from merchants department and partners in china region got together witnessing the company’s first clinical diagnosis device hitting the market. the device will be promoted together with indocyanine green for injection, a product of eisai (liaoning) pharmaceutical co. ltd. this is an attempt of eisai china to expend its business to a new field, which will enrich its product line in the treatment of hepatic diseases such as hepatic carcinoma, hepatic injury, hepatic encephalopathy, and etc., greatly improve its market competitiveness and provide better solution of diagnosis and treatment for both doctors and patients in china.